

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC

CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

DRUG REGISTRATION APPROVAL OF THE GROUP'S "CLOPIDOGREL BISULFATE TABLETS"

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the "Clopidogrel Bisulfate Tablets (75mg)" (the "**Product**") developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Group, has been granted drug registration approval by the National Medical Products Administration of the People's Republic of China.

The Product is a prodrug that is metabolized through CYP450 enzyme to produce an active metabolite to inhibit platelet aggregation. The active metabolite selectively inhibits the binding of adenosine diphosphate (ADP) with platelet receptor in order to prevent platelet aggregation. It is clinically used for the prevention of atherothrombotic event in patients with recent myocardial infarction, ischemic stroke, established peripheral artery diseases or acute coronary syndrome, with strong curative effect and low side effect.

With the improvement of living standard in China and the intensification of aging population, the incidence and mortality rate of cardiovascular and cerebrovascular diseases are gradually increasing year by year. It is expected that the Product has significant market potential and clinical application prospects. The launch of the Product will further enrich the product portfolio of the Group and contribute to the Group's development in the cardiovascular and cerebrovascular fields.

* *for identification purpose only*

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 10 June 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.